Dashboard
Manage Tickers

DMACDiaMedica Therapeutics Inc.

Nasdaq diamedica.com


$ 2.89 $ 0.01 (0.35 %)    

Friday, 05-Jul-2024 15:57:37 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 2.9
$ 2.89
$ 0.00 x 0
$ 0.00 x 0
$ 2.86 - $ 2.94
$ 1.94 - $ 4.33
34,924
na
110.1M
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-19-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-28-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-10-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-13-2020 03-31-2020 10-Q
18 03-23-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-13-2019 03-31-2019 10-Q
22 03-19-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

diamedica-therapeutics-announces-118m-private-placement-will-issue-a-total-of-472m-common-shares-at-a-purchase-price-of-250-per-share
DiaMedica Therapeutics Announces $11.8M Pr...
06/26/2024 12:17:40

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments fo...

diamedica-therapeutics-announces-expansion-of-dm199-program-into-preeclampsia
DiaMedica Therapeutics Announces Expansion...
06/26/2024 12:01:10

 Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024Key Proof-of-Concept Resu...

diamedica-therapeutics-q1-2024-gaap-eps-014-beats-016-estimate
DiaMedica Therapeutics Q1 2024 GAAP EPS $(...
05/08/2024 22:39:50

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate o...

craig-hallum-assumes-diamedica-therapeutics-at-buy-announces-price-target-of-8
Craig-Hallum Assumes DiaMedica Therapeutic...
04/24/2024 17:33:22

Craig-Hallum analyst Alexander Nowak assumes DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and announces Price Targ...

diamedica-therapeutics-doses-first-patient-relaunch-of-pivotal-phase-23-remedy2-trial-of-dm199-for-acute-ischemic-stroke
DiaMedica Therapeutics Doses First Patient...
04/17/2024 20:08:51

craig-hallum-maintains-buy-on-diamedica-therapeutics-lowers-price-target-to-8
Craig-Hallum Maintains Buy on DiaMedica Th...
03/21/2024 18:31:19

Craig-Hallum analyst Alexander Nowak maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and lowers the price target f...

oppenheimer-reiterates-outperform-on-diamedica-therapeutics-lowers-price-target-to-6
Oppenheimer Reiterates Outperform on DiaMe...
03/21/2024 12:43:47

Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Outperform and lowers the pric...

recap-diamedica-therapeutics-q4-earnings
Recap: DiaMedica Therapeutics Q4 Earnings
03/19/2024 21:25:11

diamedica-therapeutics-fy23-eps-060-vs-052-yoy-53m-cash-with-runway-to-2026
DiaMedica Therapeutics FY23 EPS $(0.60) Vs...
03/19/2024 20:31:05

Financial ResultsResearch and development (R&D) expenses increased to $13.1 million for the year ended December 31, 2023, u...

diamedica-therapeutics-q3-eps-012-beats-013-estimate
DiaMedica Therapeutics Q3 EPS $(0.12) Beat...
11/13/2023 21:57:37

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate o...

earnings-scheduled-for-november-13-2023
Earnings Scheduled For November 13, 2023
11/13/2023 11:40:53

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr...

earnings-outlook-for-diamedica-therapeutics
Earnings Outlook For DiaMedica Therapeutics
11/10/2023 17:02:09

diamedica-therapeutics-q2-eps-016-beats-018-estimate
DiaMedica Therapeutics Q2 EPS $(0.16) Beat...
08/14/2023 20:48:05

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate o...

earnings-scheduled-for-august-14-2023
Earnings Scheduled For August 14, 2023
08/14/2023 10:45:55

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per ...

benzingas-top-ratings-upgrades-downgrades-for-june-22-2023
Benzinga's Top Ratings Upgrades, Downgrade...
06/22/2023 15:02:26

oppenheimer-upgrades-diamedica-therapeutics-to-outperform-announces-7-price-target
Oppenheimer Upgrades DiaMedica Therapeutic...
06/22/2023 11:16:31

Oppenheimer analyst Francois Brisebois upgrades DiaMedica Therapeutics (NASDAQ:DMAC) from Perform to Outperform and announce...

diamedica-raises-375m-via-equity-offering-aiding-development-activities-for-dm199
DiaMedica Raises $37.5M Via Equity Offerin...
06/21/2023 15:40:11

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide ...

diamedica-therapeutics-announces-375m-private-placement-of-11011406-common-shares-at-a-purchase-price-of-340share
DiaMedica Therapeutics Announces $37.5M Pr...
06/21/2023 12:42:03

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments fo...

diamedica-therapeutics-announces-that-the-fda-has-removed-the-clinical-hold-on-dm199-phase-23-trial-for-ischemic-stroke
DiaMedica Therapeutics Announces That The ...
06/21/2023 12:16:48

DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments fo...

diamedica-therapeutics-included-in-response-to-fda-is-protocol-amendment-to-incorporate-reduced-dose-for-intravenous-administration-of-dm199
Diamedica Therapeutics Included In Respons...
05/22/2023 21:18:11

- 8K Filing 

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)